We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

By LabMedica International staff writers
Posted on 10 Jul 2025

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. More...

For patients with lung adenocarcinoma, a critical step in treatment is genetic testing to detect mutations in the tumor’s DNA. These mutations help doctors select personalized treatments, but the genetic tests required are not only costly but also slow and can create barriers to timely care. Now, a new study suggests that artificial intelligence (AI) has the potential to streamline cancer care by accurately predicting genetic mutations from routine pathology slides, reducing the need for rapid genetic testing and improving the efficiency of clinical decision-making.

Researchers at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) and Memorial Sloan Kettering Cancer Center (New York, NY, USA) have developed an AI model that can predict genetic mutations using standard H&E-stained pathology slides. This innovative approach was trained using a large dataset of lung adenocarcinoma pathology slides matched with next-generation sequencing results. The model analyzes these slides, typically used for routine diagnostic biopsies, to detect mutations like those in the EGFR gene. By identifying EGFR mutations, which are crucial for selecting targeted therapies, the AI model can potentially reduce the reliance on expensive and time-consuming genetic tests, offering a faster and more accessible alternative for personalized cancer treatment.

The AI model was tested on live patient samples at Memorial Sloan Kettering Cancer Center as part of a real-time "silent trial." The findings, published in Nature Medicine, showed that the AI could reliably predict EGFR mutations and reduce the need for rapid genetic tests by more than 40%. This is a significant step forward in integrating AI into cancer diagnostics. The researchers plan to expand this AI model to detect other cancer-related mutations and broaden its applications, aiming for regulatory approval and eventual clinical use in diverse healthcare settings. This could ultimately lead to faster diagnosis, more personalized treatment, and better patient outcomes.

“Our findings show that AI can extract critical genetic insights directly from routine pathology slides,” said Gabriele Campanella, PhD, Assistant Professor of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai. “This could streamline clinical decision-making, conserve valuable resources, and accelerate patients’ access to targeted therapies by reducing reliance on certain rapid genetic tests.”

Related Links:
Icahn School of Medicine at Mount Sina 
Memorial Sloan Kettering Cancer Center Sinai


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new test is redefining access to early endometrial cancer detection (Photo courtesy of Shutterstock)

Non-Invasive Liquid-Based Cytology Test Enables Early Endometrial Cancer Detection

Endometrial cancer is the fourth most common cancer among women in the United States, with over 69,000 new cases expected in 2025. Yet many diagnoses occur late, particularly in women who face inconclusive... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.